RxDoctor Payments Data

Daniel Hardy, MD

Neurology · Richmond, VANPI 1932179462

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $332,571 of the $382,170 with a category attached, or 87.0%. 60 manufacturers reported payments, led by EMD Serono, Inc. at 52.5% of the total. 2025 is the largest year on record at $96,853, 2.4 times the $41,162 reported in 2019. Among neurology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$382,170in general payments, 2019–2025

Across 1,386 payments — averaging $275.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$201K
  • Biogen$80K
  • AbbVie$49K
  • Pfizer$20K
  • Biohaven Pharmaceuticals, Inc.$15K
  • Biohaven Pharmaceutical Holding Company Ltd.$6K
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$8,0722%
  • Speaking & faculty fees$332,57187%
  • Travel & lodging$12,5483%
  • Food & beverage$28,5427%
  • Education$4370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.296$200,679
Biogen150$79,708
AbbVie(2 entities)228$48,610
Pfizer34$19,730
Biohaven Pharmaceuticals, Inc.32$14,767
Biohaven Pharmaceutical Holding Company Ltd.17$5,863
UCB, Inc.92$1,767
Genentech USA, Inc.25$932
Novartis56$900
AstraZeneca(2 entities)27$689
Amgen(2 entities)28$627
Sanofi25$596
SK Life Science, Inc.19$464
Bristol Myers Squibb48$408
Teva Pharmaceuticals USA, Inc.18$383
Lundbeck LLC18$342
Lilly USA, LLC20$329
Amneal Pharmaceuticals LLC18$297
Harmony Biosciences LLC11$278
Eisai Inc.10$278
Johnson & Johnson(2 entities)11$269
Grifols USA, LLC12$253
TG Therapeutics, Inc.11$241
Neurelis, Inc.16$233
MDD US Operations, LLC12$229
Kyowa Kirin, Inc.11$214
Sunovion Pharmaceuticals Inc.12$199
Mallinckrodt Hospital Products Inc.6$175
Acadia Pharmaceuticals Inc7$157
Argenx US, Inc.5$154
Neurocrine Biosciences, Inc.9$145
CSL Behring7$133
Jazz Pharmaceuticals Inc.6$133
Banner Life Sciences, LLC5$131
E.r. Squibb & Sons, L.L.C.1$125
Alnylam Pharmaceuticals Inc.7$122
ANI Pharmaceuticals, Inc.5$121
Merz Pharmaceuticals, LLC4$116
Merz North America, Inc.4$112
Avanir Pharmaceuticals, Inc.6$105
Greenwich Biosciences, Inc.5$95
Axsome Therapeutics, Inc.4$85
Catalyst Pharmaceuticals, Inc.4$82
Otsuka America Pharmaceutical, Inc.3$74
Cycle Pharmaceuticals Inc3$70
Abbott3$67
Supernus Pharmaceuticals, Inc.3$60
Immedica Pharma US, Inc.2$60
Acorda Therapeutics, Inc4$57
Impel Pharmaceuticals Inc.3$56
Life Molecular Imaging Ltd1$48
Promius Pharma LLC2$39
Sumitomo Pharma America, Inc.2$33
Genentech, Inc.1$31
Microtransponder, Inc.1$29
Springworks Therapeutics, Inc.1$26
Ipsen Biopharmaceuticals, Inc1$22
Avadel CNS Pharmaceuticals, LLC1$22
Bausch Health US, LLC1$19
Averitas Pharma Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$382,170 in reported general payments places this provider in the 95th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$173,559
Medicare patients
609
Services billed
12,910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide14$131,602
VumerityDiroximel Fumarate11$92,032
Nurtec OdtRimegepant Sulfate35$44,167
UbrelvyUbrogepant31$41,746
GlatopaGlatiramer Acetate13$34,944
Emgality PenGalcanezumab-Gnlm37$27,963
Aimovig AutoinjectorErenumab-Aooe23$22,930
QuliptaAtogepant11$13,383
Teriflunomide22$9,224
Eletriptan HbrEletriptan Hydrobromide26$7,898
Sumatriptan Succinate114$4,839
Memantine Hcl ErMemantine Hcl14$3,709
Donepezil Hcl359$3,358
Carbamazepine ErCarbamazepine18$3,299
Pregabalin46$3,109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$596$131,60214 claims
BiogenVumerity$79,708$92,03211 claims
AbbVieUbrelvy, Qulipta$48,610$55,12942 claims
PfizerNurtec Odt$19,730$44,16735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 neurology providers in Virginia.

Other neurology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →